1-3 of 3
Ghazi Damanhouri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Ali Taher, Amal El-Beshlawy, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri
Journal: Blood
Blood (2008) 112 (11): 5409.
https://doi.org/10.1182/blood.V112.11.5409.5409
Published: 2008
Journal Articles

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dany Habr, Abdel Hmissi, Amal El-Beshlawy
Journal: Blood
Blood (2008) 112 (11): 3879.
https://doi.org/10.1182/blood.V112.11.3879.3879
Published: 2008
Journal Articles

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dietrich Pfluger, Dominik Hadler, Amal El-Beshlawy
Journal: Blood
Blood (2007) 110 (11): 2779.
https://doi.org/10.1182/blood.V110.11.2779.2779
Published: 2007